Group 1 - Bid Medicine's stock price fell by 5.04% on January 20, closing at 66.00 yuan per share, with a trading volume of 52.74 million yuan and a turnover rate of 1.81%, resulting in a total market capitalization of 5.998 billion yuan [1] - The stock has experienced a continuous decline over three days, with a cumulative drop of 6.12% during this period [1] - Bid Medicine focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] Group 2 - Among the top ten circulating shareholders of Bid Medicine, a fund under E Fund, specifically E Fund Value Growth Mixed Fund (110010), entered the top ten with 900,000 shares, accounting for 2.08% of circulating shares [2] - The estimated floating loss for E Fund Value Growth Mixed Fund today is approximately 3.15 million yuan, with a total floating loss of 4.077 million yuan during the three-day decline [2] - E Fund Value Growth Mixed Fund has a total asset size of 3.288 billion yuan, with a year-to-date return of 3.74% and a one-year return of 38.06% [2]

Market Overview - On January 13, the A-share market saw a collective decline in the three major indices, with the Shanghai Composite Index closing at 4163.84 points, down 0.03% [2] - The Shenzhen Component Index fell by 0.31%, and the ChiNext Index decreased by 0.83% [2][3] - A total of 2427 stocks rose while 2862 stocks fell, indicating a mixed market sentiment [3] Sector Performance - The healthcare services, lithium mining, precious metals, and insurance sectors showed strong performance, while sectors such as commercial aerospace, communication equipment, and shipbuilding faced declines [3][4] - Lithium mining stocks experienced a significant surge, with companies like Tibet Summit reaching a 10% limit up, and others like Salt Lake Co. and Ganfeng Lithium rising over 7% [6][7] Lithium Mining Sector - The lithium mining sector saw a notable rally, with the main contract for lithium carbonate futures on the Shanghai Futures Exchange surpassing 170,000 yuan per ton, marking a rise of over 9% [6] - Key stocks in this sector include: - Tibet Summit: 19.49 yuan, up 9.99%, market cap of 17.8 billion yuan - Ganfeng Lithium: 72.83 yuan, up 7.15%, market cap of 144.5 billion yuan - Salt Lake Co.: 34.24 yuan, up 7.13%, market cap of 181.2 billion yuan [7] Insurance Sector - The financial sector was active, with the insurance sector showing strength. China Life Insurance rose over 3%, reaching 50.94 yuan per share, with a market cap of 1.2794 trillion yuan [10] - China Ping An increased by over 2%, priced at 68.92 yuan per share, with a market cap of 1.2034 trillion yuan [12] - Analysts predict that by 2026, new premium income for listed insurance companies will achieve double-digit growth, driven primarily by the bancassurance channel [15] AI Healthcare Sector - AI healthcare stocks were notably active, with several companies hitting the daily limit up. Notable performers included: - Nossg: 76.48 yuan, up 20.01%, market cap of 7.4 billion yuan - Pruis: 72.24 yuan, up 20.00%, market cap of 5.7 billion yuan - Hongbo Medicine: 56.64 yuan, up 20.00%, market cap of 7.9 billion yuan [18] - Nvidia announced a joint investment of $1 billion with Eli Lilly to establish an AI drug laboratory, which is expected to accelerate medical discoveries [17] Precious Metals Sector - The precious metals sector saw a significant rise, with spot gold prices reaching a record high of $4630.28 per ounce [20] - Key stocks in this sector include: - Hunan Silver: 9.21 yuan, up 9.90%, market cap of 26 billion yuan - Xiaocheng Technology: 38.54 yuan, up 8.72%, market cap of 10.6 billion yuan [21]

Group 1 - Bid Pharma's stock increased by 5.07% to 68.44 CNY per share, with a trading volume of 68.3753 million CNY and a turnover rate of 2.38%, resulting in a total market capitalization of 6.22 billion CNY [1] - The company, established on April 27, 2007, focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] - The main business revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from molecular building block aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1] Group 2 - Morgan Stanley Fund has a significant holding in Bid Pharma, with the "Morgan Stanley Youyue Anhe Mixed A" fund reducing its holdings by 15,300 shares to 53,000 shares, representing 6.6% of the fund's net value, making it the third-largest holding [2] - The fund has a total scale of 29.6292 million CNY and has achieved a year-to-date return of 8.64%, ranking 427 out of 8,827 in its category, and a one-year return of 26.74%, ranking 4,492 out of 8,084 [2]

Group 1 - Bid Pharma announced that as of the disclosure date, shareholder Zhoushan Xinxie Enterprise Management Partnership holds approximately 4.72 million unrestricted shares, accounting for 5.19% of the total shares [1] - Shareholder Zhoushan Landan Enterprise Management Partnership holds about 3.58 million shares, representing 3.94% of the total shares, with approximately 6.95 thousand shares being restricted and about 3.51 million shares being unrestricted [1] - Shareholder Wu Bo holds approximately 785.8 thousand unrestricted shares, which is 0.86% of the total shares [1] Group 2 - Xinxie Management, Landan Management, and Wu Bo are acting in concert, collectively holding 10% of Bid Pharma's shares [1] - Due to liquidity needs, these shareholders plan to reduce their holdings within three months after the disclosure of the reduction plan, starting 15 trading days from the announcement [1] - Xinxie Management plans to reduce up to approximately 1.0361 million shares through block trading and up to approximately 363.5 thousand shares through centralized bidding, while Landan Management and Wu Bo have similar reduction plans [1]

Core Viewpoint - Bidu Pharmaceutical (688073.SH) announced a share reduction plan by its shareholders due to liquidity needs, involving a total of up to 336,000 shares, which represents approximately 2.6% of the company's total share capital [1] Group 1: Shareholder Reduction Plans - Shareholder Xinxin Management plans to reduce its holdings by up to 1.14% of the total share capital through block trades and 0.40% through centralized bidding [1] - Shareholder Landan Management intends to reduce its holdings by up to 0.86% through block trades and 0.40% through centralized bidding [1] - Shareholder Wu Bo plans to reduce his holdings by up to 0.20% through centralized bidding [1]

Core Viewpoint - Bidu Pharmaceutical (688073.SH) announced a share reduction plan by its shareholders due to liquidity needs, involving a total of up to 336,000 shares, which represents approximately 2.6% of the company's total share capital [1] Group 1: Shareholder Reduction Plans - Shareholder Xinxin Management plans to reduce its holdings by up to 1.14% of the total share capital through block trades and 0.40% through centralized bidding [1] - Shareholder Landan Management intends to reduce its holdings by up to 0.86% through block trades and 0.40% through centralized bidding [1] - Shareholder Wu Bo plans to reduce his holdings by up to 0.20% through centralized bidding [1]

Core Viewpoint - Bid Pharma (688073.SH) announced a share reduction plan by its shareholders due to personal liquidity needs, involving multiple parties and specific share quantities to be sold through different trading methods [1] Shareholder Reduction Plan - Shareholder Xinxin Management plans to reduce its holdings by up to 1,036,065 shares through block trading, representing 1.14% of the total share capital, and up to 363,532 shares through centralized bidding, representing 0.40% of the total share capital [1] - Shareholder Landan Management intends to reduce its holdings by up to 781,593 shares through block trading, representing 0.86% of the total share capital, and up to 363,532 shares through centralized bidding, also representing 0.40% of the total share capital [1] - Shareholder Wu Bo plans to reduce his holdings by up to 181,766 shares through centralized bidding, representing 0.20% of the total share capital [1]

证券代码：688073 证券简称：毕得医药 公告编号：2026-003 上海毕得医药科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 欣曦管理、兰旦管理所持股份来源为公司首次公开发行并上市前取得的股份 及公司权益分派由资本公积转增股本方式取得的股份，吴波本次拟减持的股份系 公司原股东宁波鼎华永创创业投资合伙企业（有限合伙）（以下简称"鼎华永创"） 解散后，通过证券非交易过户的方式取得。 大股东持有的基本情况 截至本公告披露日，上海毕得医药科技股份有限公司（以下简称"毕得医药" 或"公司"）股东舟山欣曦企业管理合伙企业（有限合伙）（以下简称"欣曦管理"） 持有公司无限售条件流通股 4,717,881 股，占公司股份总数的 5.19%。股东舟山 兰旦企业管理合伙企业（有限合伙）（以下简称"兰旦管理"）持有公司股份 3,584,615 股，占公司股份总数的 3.94%，其中 69,486 股为有限售条件流通股， 3,515,129 股为无限售条件流通股。股东吴波持 ...

Core Viewpoint - Bid Pharma (688073.SH) announced a share reduction plan by its shareholders due to personal liquidity needs, involving multiple parties and specific share quantities to be sold through different trading methods [1] Group 1: Shareholder Reduction Plans - Shareholder Xinxin Management plans to reduce its holdings by up to 1,036,065 shares through block trading, representing 1.14% of the total share capital, and up to 363,532 shares through centralized bidding, representing 0.40% of the total share capital [1] - Shareholder Landan Management intends to reduce its holdings by up to 781,593 shares through block trading, representing 0.86% of the total share capital, and up to 363,532 shares through centralized bidding, also representing 0.40% of the total share capital [1] - Shareholder Wu Bo plans to reduce his holdings by up to 181,766 shares through centralized bidding, representing 0.20% of the total share capital [1]

Core Viewpoint - The announcement from Bid Pharma indicates that shareholders Xinxin Management, Landan Management, and Wu Bo plan to reduce their holdings by up to 3.00% within three months after the disclosure date, primarily due to funding needs [1] Shareholder Reduction Plans - Xinxin Management intends to reduce its holdings through block trading by up to 1.14% and through centralized bidding by up to 0.40% [1] - Landan Management plans to reduce its holdings through block trading by up to 0.86% and through centralized bidding by up to 0.40% [1] - Wu Bo aims to reduce his holdings through centralized bidding by up to 0.20% [1] Impact on Company - The reduction in shareholding is not expected to have a significant impact on the company's governance structure, ownership structure, or ongoing operations [1]